Betaloc CR 23.75 New Zealand - English - Medsafe (Medicines Safety Authority)

betaloc cr 23.75

astrazeneca limited - metoprolol succinate 23.75mg;   - modified release tablet - 23.75 mg - active: metoprolol succinate 23.75mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

FEIBA-NF factor VIII inhibitor bypassing fraction 2500U powder for injection vial with diluent vial Australia - English - Department of Health (Therapeutic Goods Administration)

feiba-nf factor viii inhibitor bypassing fraction 2500u powder for injection vial with diluent vial

takeda pharmaceuticals australia pty ltd - factor viii inhibitor bypassing fraction, quantity: 1000 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; sodium chloride - feiba-nf is indicated for routine prophylaxis, control of spontaneous bleeding episodes and use in surgery in haemophilia a or b patients with inhibitors.